{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:57:49Z","timestamp":1790279869321,"version":"4.1.0"},"update-to":[{"DOI":"10.1371\/journal.pntd.0009181","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000}}],"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>Ensuring access to essential medicines for leishmaniasis control is challenging, as leishmaniasis is a very small and unattractive market for pharmaceutical industry. Furthermore, control programmes are severely underfunded. We conducted an analysis of global procurement of leishmaniasis medicines for the past 5 years in order to shed light on the current leishmaniasis market landscape and supply and demand dynamics. We estimated global demand of each leishmaniasis medicines, the amount of each medicine required to treat all reported cases, based on the number of cases reported to WHO and the first-line treatment regimen used in each country. Procurement data were obtained from procurement agencies, international organizations, WHO, national leishmaniasis programmes and manufacturers. Expert interviews were conducted to have a better understanding of how medicines were procured and used. The comparison of estimated need and procurement data indicated discrepancies in supply and demand at global level as well as in the most endemic countries. The extent of the gap in supply was up to 80% of the needs for one of the leishmaniasis medicines. Mismatch between supply and demand was much wider for cutaneous leishmaniasis than visceral leishmaniasis. This study presents a current picture of procurement patterns and imbalance in global supply and demand. Addressing improved access and supply barriers requires concerted and coordinated efforts at the global and national levels. Priority actions include setting up a procurement coordination mechanism among major procurers, partners and national programmes where forecasting and supply planning is jointly developed and communicated with manufacturers. In addition, continuous engagement of manufacturers and advocacy is critical to diversify the supplier base and ensure quality-assured and affordable generic medicines for leishmaniasis.<\/jats:p>","DOI":"10.1371\/journal.pntd.0009181","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T20:26:35Z","timestamp":1613679995000},"page":"e0009181","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":47,"title":["The global procurement landscape of leishmaniasis medicines"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9638-3653","authenticated-orcid":true,"given":"Hye Lynn","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7245-5886","authenticated-orcid":true,"given":"Saurabh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Ruiz Postigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Borisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Argaw","family":"Dagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"key":"pntd.0009181.ref001","unstructured":"World Health Organization. Everybody business: strengthening health systems to improve health outcomes: WHO\u2019s framework for action. 2007. Available from: https:\/\/www.who.int\/healthsystems\/strategy\/everybodys_business.pdf."},{"key":"pntd.0009181.ref002","unstructured":"World Health Organization. Sustainable Development Goal 3: Health. 2015. Available from: https:\/\/www.who.int\/topics\/sustainable-development-goals\/targets\/en\/."},{"key":"pntd.0009181.ref003","unstructured":"World Health Organization. First WHO report on neglected tropical diseases: working to overcome the global impact of neglected tropical diseases 2010. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/44440\/9789241564090_eng.pdf?sequence=1."},{"key":"pntd.0009181.ref004","first-page":"186","article-title":"Control of the leishmaniases","volume":"949","author":"World Health Organization","year":"2010","journal-title":"World Health Organ Tech Rep Ser"},{"issue":"10053","key":"pntd.0009181.ref005","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(16)31460-X","article-title":"Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"GBD 2015 DALYs and HALE Collaborators","year":"2016","journal-title":"Lancet"},{"key":"pntd.0009181.ref006","unstructured":"World Health Organization. Weekly epidemiological record, No 22. 2016;91;285\u2013296. Available from: https:\/\/www.who.int\/wer\/2016\/wer9122.pdf?ua=1."},{"key":"pntd.0009181.ref007","unstructured":"World Health Organization. Global Health Estimates, cause-specific Mortality 2016. Available from: https:\/\/www.who.int\/healthinfo\/global_burden_disease\/estimates\/en\/."},{"key":"pntd.0009181.ref008","first-page":"8463097","article-title":"Incidence and Trends of Leishmaniasis and Its Risk Factors in Humera","volume":"2018","author":"DG Tedla","year":"2018","journal-title":"Western Tigray J Parasitol Res"},{"issue":"1","key":"pntd.0009181.ref009","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/qjmed\/hct116","article-title":"Leishmaniasis: clinical syndromes and treatment","volume":"107","author":"BS McGwire","year":"2014","journal-title":"QJM"},{"key":"pntd.0009181.ref010","unstructured":"World Health Organization. Weekly epidemiological record, No 25. 2020;95;265\u2013280. Available from: file:\/\/\/C:\/Users\/hchoi\/Downloads\/WER9525-eng-fre.pdf."},{"key":"pntd.0009181.ref011","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1473-3099(03)00517-6","article-title":"Post-kala-azar dermal leishmaniasis","volume":"3","author":"EE Zijlstra","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"pntd.0009181.ref012","unstructured":"World Health Organization. World Health Assembly resolution and decisions, WHA60.13 Control of leishmaniasis. 2007. Available from: https:\/\/www.who.int\/neglected_diseases\/mediacentre\/WHA_60.13_Eng.pdf?ua=1."},{"key":"pntd.0009181.ref013","unstructured":"World Health Organization. WHO launches global consultations for a new Roadmap on neglected tropical diseases. 2019. Available from: https:\/\/www.who.int\/neglected_diseases\/news\/WHO-launches-global-consultations-for-new-NTD-Roadmap\/en\/."},{"key":"pntd.0009181.ref014","first-page":"e00048","article-title":"Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls","volume":"31","author":"F Alves","year":"2018","journal-title":"Perspectives Clin Microbiol Rev"},{"issue":"6","key":"pntd.0009181.ref015","doi-asserted-by":"crossref","first-page":"e1674","DOI":"10.1371\/journal.pntd.0001674","article-title":"Sodium stibogluconate (ssg) & paromomycin combination compared to ssg for visceral leishmaniasis in east Africa: a randomised controlled trial","volume":"6","author":"A Musa","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009181.ref016","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/tmi.12238","article-title":"Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?","volume":"19","author":"NA Salih","year":"2014","journal-title":"Tropical Med Int Health"},{"key":"pntd.0009181.ref017","first-page":"193","article-title":"Visceral leishmaniasis and HIV coinfection: current perspectives","volume":"10","author":"JAL Lindoso","year":"2018","journal-title":"HIV AIDS (Auckl)"},{"key":"pntd.0009181.ref018","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa0903627","article-title":"Single-dose liposomal amphotericin B for visceral leishmaniasis in India","volume":"362","author":"S Sundar","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"pntd.0009181.ref019","doi-asserted-by":"crossref","first-page":"e2603","DOI":"10.1371\/journal.pntd.0002603","article-title":"Five-Year Field Results and Long-Term Effectiveness of 20 mg\/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India","volume":"8","author":"S Burza","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"pntd.0009181.ref020","doi-asserted-by":"crossref","first-page":"e0003699","DOI":"10.1371\/journal.pntd.0003699","article-title":"Effectiveness and Safety of Short Course Liposomal Amphotericin B (AmBisome) as First Line Treatment for Visceral Leishmaniasis in Bangladesh","volume":"9","author":"E Lucero","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009181.ref021","unstructured":"World Health Organization. Fourth Regional Technical Advisory Group Meeting on Elimination of Kala-azar, 12\u201314. Kathmandu, Nepal. July 2011:2011."},{"key":"pntd.0009181.ref022","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4172\/2167-7719.1000129","article-title":"Therapeutic Options of Cutaneous Leishmaniasis","volume":"5","author":"A Oryan","year":"2016","journal-title":"Air Water Borne Dis"},{"key":"pntd.0009181.ref023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005877","article-title":"Post-kala-azar dermal leishmaniasis in the Indian subcontinent: a threat to the South-East Asia Region Kala-azar Elimination Programme","volume":"11","author":"EE Zijlstra","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009181.ref024","unstructured":"WHO. Post-kala-azar dermal leishmaniasis: a manual for case management and control. 2013."},{"key":"pntd.0009181.ref025","first-page":"135","volume-title":"Equity, social determinants and public health programmes","author":"J Aagaard-Hansen","year":"2010"},{"key":"pntd.0009181.ref026","doi-asserted-by":"crossref","first-page":"e029141","DOI":"10.1136\/bmjopen-2019-029141","article-title":"Exploring global and country-level barriers to an effective supply of leishmaniasis medicines and diagnostics in eastern Africa: a qualitative study","volume":"9","author":"T Sunyoto","year":"2019","journal-title":"BMJ Open"},{"key":"pntd.0009181.ref027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/126093","article-title":"Visceral leishmaniasis clinical management in endemic districts of India, Nepal, and bangladesh","volume":"2012","author":"MR Banjara","year":"2012","journal-title":"J Trop Med"},{"issue":"10","key":"pntd.0009181.ref028","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1469-0691.2011.03635.x","article-title":"Leishmaniasis impact and treatment access","volume":"17","author":"M den Boer","year":"2011","journal-title":"Clinical Microbiology and Infection"},{"issue":"3","key":"pntd.0009181.ref029","doi-asserted-by":"crossref","first-page":"e000709","DOI":"10.1136\/bmjgh-2018-000709","article-title":"Why miltefosine-a life-saving drug for leishmaniasis-is unavailable to people who need it the most","volume":"3","author":"T Sunyoto","year":"2018","journal-title":"BMJ Glob Health"},{"key":"pntd.0009181.ref030","doi-asserted-by":"crossref","first-page":"e1544","DOI":"10.1371\/journal.pntd.0001544","article-title":"A poor-quality generic drug for the treatment of visceral leishmaniasis: a case report and appeal","volume":"6","author":"TP Dorlo","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009181.ref031","unstructured":"World Health Organization. Falsified meglumine antimoniate ampoules in Iran and Pakistan. Medical Product Alert N\u00b0 7\/2019. 2019. Available from: https:\/\/www.who.int\/medicines\/publications\/drugalerts\/drug_alert-7-2019\/en\/."},{"issue":"1","key":"pntd.0009181.ref032","doi-asserted-by":"crossref","first-page":"e0006988","DOI":"10.1371\/journal.pntd.0006988","article-title":"A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia","volume":"13","author":"E Diro","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"pntd.0009181.ref033","doi-asserted-by":"crossref","first-page":"e0006527","DOI":"10.1371\/journal.pntd.0006527","article-title":"The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study","volume":"12","author":"C Abongomera","year":"2018","journal-title":"PLoS Negl Trop Dis"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0009181","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T18:55:34Z","timestamp":1614711334000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009181"}},"subtitle":[],"editor":[{"given":"Gregory","family":"Deye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0009181","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0009181","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]}}}